[BPTH] Bio-Path Holdings, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 1.3 Change: 0.06 (4.84%)
Ext. hours: Change: 0 (0%)

chart BPTH

Refresh chart

Strongest Trends Summary For BPTH

BPTH is in the medium-term down -81% in 5 months. In the long-term down -91% in 7 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Bio-Path Holdings, Inc., a biotechnology company, focuses on developing therapeutic products utilizing its proprietary liposomal delivery technology to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion in the United States. Its principal product is Liposomal Grb-2, which is in a Phase I study for blood cancers, as well as in preclinical studies for triple negative and inflammatory breast cancers. The company is also developing Liposomal Bcl-2, which is a liposome delivered antisense cancer drug for treating lymphoma, breast cancer, colon cancer, prostate cancer, and leukemia. It has license agreement with MD Anderson Cancer Center relating to the delivery technology platform for antisense nucleic acids, including two single nucleic acid drug products. Bio-Path Holdings, Inc. was founded in 2007 and is based in Houston, Texas.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-0.05 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-7
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-37.83% ROE-39.54% ROI
Current Ratio21 Quick Ratio Long Term Debt/Equity Debt Ratio0.05
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities Cash From Investing Activities Cash From Operating Activities-1.41 M Gross Profit
Net Profit-1.37 M Operating Profit-1.38 M Total Assets14.25 M Total Current Assets12.94 M
Total Current Liabilities620 K Total Debt Total Liabilities620 K Total Revenue
Technical Data
High 52 week12.82 Low 52 week0.59 Last close2.12 Last change-3.64%
RSI41.54 Average true range0.18 Beta0.15 Volume147.73 K
Simple moving average 20 days0.65% Simple moving average 50 days-30.17% Simple moving average 200 days-43.5%
Performance Data
Performance Week-0.93% Performance Month10.42% Performance Quart-80.37% Performance Half44.22%
Performance Year27.62% Performance Year-to-date-39.43% Volatility daily3.31% Volatility weekly7.39%
Volatility monthly15.15% Volatility yearly52.47% Relative Volume350.45% Average Volume553.56 K
New High New Low

News

2019-03-21 06:13:08 | Should You Buy Bio-Path Stock After 5-Fold Gain? 3 Pros, 3 Cons

2019-03-20 09:15:01 | Bio-Path Holdings Reports Full Year 2018 Financial Results

2019-03-20 06:30:00 | Bio-Path Holdings, Inc. to Host Earnings Call

2019-03-15 16:01:00 | Bio-Path Holdings to Announce Fourth Quarter and Full Year 2018 Financial Results on March 20, 2019

2019-03-14 15:10:00 | Bio-Path Holdings, Inc. Announces Closing of $18.5 Million Registered Direct Offering of Common Stock

2019-03-12 09:15:00 | Bio-Path Holdings, Inc. Announces $18.5 Million Registered Direct Offering of Common Stock

2019-03-08 13:25:18 | The Secret To Trading Stocks Like Bio-Path That Helped Me Quit My Desk Job And Make Thousands

2019-03-08 07:30:00 | The Device Market That Drove One Company From $2.50 to $65 Has a New Entrant

2019-03-07 11:55:50 | Traders Mystified by 3000% Surge in Shares of Cancer-Drug Maker

2019-03-07 10:35:00 | UPDATE: Bio-Path stock gains another 130% on Thursday

2019-03-06 14:35:00 | Bio-Path Holdings Updates Clinical Trial Data and it Sounds Promising

2019-03-06 14:30:00 | Bio-Path stock soars in active trade after announcing Phase 2 trial update

2019-03-06 13:27:11 | Bio-Path Holdings News: Why BPTH Stock Is Skyrocketing Today

2019-03-06 10:00:00 | Under the Radar Cannabis Stock-THC Therapeutics, Inc.

2019-03-06 08:00:00 | Bio-Path Announces Clinical Update to Interim Analysis of Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia

2019-03-04 06:10:38 | Is Bio-Path Holdings, Inc.’s NASDAQ:BPTH CEO Pay Justified?

2019-02-28 08:00:00 | Bio-Path Holdings to Present Data at the 2019 AACR Annual Meeting

2019-01-24 16:30:00 | Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. NASDAQ: BPTH

2019-01-23 16:01:00 | Bio-Path Holdings, Inc. Announces Closing of $1.7 Million Registered Direct Offering Priced At-the-Market

2019-01-18 12:31:35 | Bio-Path Holdings, Inc. Announces $1.7 Million Registered Direct Offering Priced At-the-Market

2019-01-18 08:00:00 | Bio-Path Holdings Announces 1-for-20 Reverse Stock Split

2019-01-17 16:07:02 | Bio-Path Holdings, Inc. Announces Closing of Public Offering of Common Stock

2019-01-16 08:24:33 | The Daily Biotech Pulse: Revance Common Stock Offering, Adcom Catalyst For Amgen

2019-01-14 22:23:31 | Bio-Path Holdings, Inc. Announces Pricing of Public Offering of Common Stock

2019-01-14 16:01:00 | Bio-Path Holdings, Inc. Announces Proposed Public Offering of Common Stock

2018-12-27 08:49:36 | Bio-Path Holdings Provides Clinical Update and 2019 Business Outlook

2018-12-26 09:47:00 | Could Bio-Path Holdings, Inc.’s NASDAQ:BPTH Investor Composition Influence The Stock Price?

2018-12-03 07:22:18 | Bio-Path Holdings Presents Interim Data from Phase 2 Study Evaluating Prexigebersen as a Treatment for Acute Myeloid Leukemia at the 60th Annual American Society of Hematology Annual Meeting

2018-11-25 09:41:17 | The Week Ahead In Biotech: ASH 2018, PDUFA Dates, Clinical Trials And Earnings

2018-11-15 07:20:33 | Bio-Path: 3Q Earnings Snapshot

2018-11-15 07:00:00 | Bio-Path Holdings Reports Third Quarter 2018 Financial Results

2018-11-08 16:01:00 | Bio-Path Holdings to Announce Third Quarter 2018 Financial Results on November 15, 2018

2018-11-01 09:05:00 | Bio-Path Holdings to Present Clinical Data at the 60th Annual American Society of Hematology Annual Meeting

2018-10-09 13:11:05 | What does Bio-Path Holdings Inc’s NASDAQ:BPTH Balance Sheet Tell Us About Its Future?

2018-09-25 16:01:00 | Bio-Path Holdings, Inc. Announces Closing of $1.5 Million Registered Direct Offering

2018-09-21 06:30:00 | Bio-Path Holdings, Inc. Announces $1.5 Million Registered Direct Offering

2018-08-29 08:00:00 | Bio-Path Holdings to Present at the H.C. Wainwright 20th Annual Global Investment Conference

2018-08-27 07:30:00 | Bio-Path Holdings Announces First Patient Dosed in Expansion of Phase 2 Trial of Prexigebersen in Acute Myeloid Leukemia

2018-08-16 10:26:20 | Bio-Path Holdings Appoints Dr. Jason B. Fleming to Scientific Advisory Board

2018-08-15 07:05:59 | Bio-Path: 2Q Earnings Snapshot

2018-08-15 07:00:00 | Bio-Path Holdings Reports Second Quarter 2018 Financial Results

2018-08-15 06:30:00 | Bio-Path Holdings, Inc. to Host Earnings Call

2018-08-08 09:15:00 | Bio-Path Holdings to Announce Second Quarter 2018 Financial Results on August 15, 2018

2018-06-26 08:00:00 | Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. NASDAQ: BPTH

2018-05-16 08:11:09 | With A -19.42% Earnings Drop, Is Bio-Path Holdings Inc’s NASDAQ:BPTH A Concern?

2018-05-16 07:08:30 | Bio-Path: 1Q Earnings Snapshot

2018-05-16 07:00:00 | Bio-Path Holdings Reports First Quarter 2018 Financial Results

2018-05-10 08:00:00 | Bio-Path Holdings Appoints Dr. Anas Younes to Scientific Advisory Board

2018-05-09 08:00:00 | Bio-Path Holdings to Announce First Quarter 2018 Financial Results on May 16, 2018

2018-04-18 16:01:00 | Pre-Clinical Data Demonstrating Promising Potential of Prexigebersen as Treatment for Solid Tumors in Gynecologic Malignancies Presented at American Association for Cancer Research Annual Meeting